Intensified Therapy Matches Standard Care for Lupus Kidney Disease
A randomized trial found intensified B-cell depletion therapy achieved comparable renal response while sharply reducing steroid exposure.
Updated on Nov. 3, 2026 in Stroke
The INTONATE trial randomized 54 patients with class III, IV, or V lupus nephritis to intensified B-cell depletion therapy or mycophenolate mofetil plus glucocorticoids. Renal response rates did not differ significantly between the two groups at 12 months.
Why it matters
Lupus nephritis is a serious kidney complication of lupus, and steroids carry substantial long-term side effects. Results suggesting comparable kidney outcomes with much less steroid use could shape how clinicians weigh treatment options.
The trial enrolled 54 participants, 27 per arm, and followed them for 30 months, with 59.3% of intensified-therapy patients versus 48.1% of standard-therapy patients achieving total renal response at 12 months. Whether the advantage in steroid reduction holds in larger, blinded trials over longer periods remains unknown.
The players
INTONATE trial
A multicenter, open-label, randomized controlled trial that compared intensified B-cell depletion therapy with standard therapy in lupus nephritis patients.
The details
Researchers compared intensified B-cell depletion therapy against mycophenolate mofetil plus glucocorticoids in patients with lupus nephritis. The intensified group reached remission without maintenance immunosuppression and showed faster response and increased flare-free survival, while anti-dsDNA levels fell in 81% of that group versus 56% of controls.
Timeline
Primary endpoint of total renal response was assessed at 12 months.
Follow-up endpoints, including sustained remission, were assessed at 30 months.
Health Landscape
The INTONATE trial adds a randomized comparison to the growing use of B-cell depletion in lupus nephritis, a field that has long relied on high-dose glucocorticoids. Its steroid-sparing signal addresses a central tradeoff clinicians have faced in managing this kidney disease.
For people with lupus nephritis, the findings suggest a treatment approach that may reduce cumulative steroid exposure without sacrificing kidney response in the short term. Patients considering therapy changes should discuss the tradeoffs with their own clinicians.
The takeaway
Lower steroid use may be achievable in lupus nephritis without losing short-term kidney response, though larger, longer studies will be needed to confirm the benefit. Readers with lupus should review options with their specialists.
Further reading
Explore more in the Stroke section for related neurological and vascular health coverage.
Source note: This article includes information reported by Derm Immuno Today.
